2018 New Drug Update.

Daniel A Hussar, Laura A Finn
{"title":"2018 New Drug Update.","authors":"Daniel A Hussar,&nbsp;Laura A Finn","doi":"10.4140/TCP.n.2018.188","DOIUrl":null,"url":null,"abstract":"<p><p>Five new drugs marketed within the last year, which are used for medical problems often experienced by the elderly, have been selected for consideration in this review. The uses and most important properties of these agents are discussed, and a rating for each new drug is determined using the New Drug Comparison Rating system developed by the author (DAH). Advantages, disadvantages, and other important information regarding each new drug are identified and used as the basis for determining the rating. The drugs include an anticoagulant, an antiparkinson agent, an agent for tardive dyskinesia, an agent for psoriasis, and an agent for constipation. The drugs reviewed are betrixaban, safinamide mesylate, valbenazine tosylate, guselkumab, and plecanatide.</p>","PeriodicalId":45985,"journal":{"name":"CONSULTANT PHARMACIST","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4140/TCP.n.2018.188","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CONSULTANT PHARMACIST","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4140/TCP.n.2018.188","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Five new drugs marketed within the last year, which are used for medical problems often experienced by the elderly, have been selected for consideration in this review. The uses and most important properties of these agents are discussed, and a rating for each new drug is determined using the New Drug Comparison Rating system developed by the author (DAH). Advantages, disadvantages, and other important information regarding each new drug are identified and used as the basis for determining the rating. The drugs include an anticoagulant, an antiparkinson agent, an agent for tardive dyskinesia, an agent for psoriasis, and an agent for constipation. The drugs reviewed are betrixaban, safinamide mesylate, valbenazine tosylate, guselkumab, and plecanatide.

2018年新药更新。
在过去一年中上市的五种新药,用于老年人经常遇到的医疗问题,已被选为本次审查的考虑因素。讨论了这些药物的用途和最重要的特性,并使用作者开发的新药比较评级系统(DAH)确定了每种新药的评级。每种新药的优点、缺点和其他重要信息被确定并用作确定评级的基础。所述药物包括抗凝血剂、抗帕金森剂、迟发性运动障碍剂、牛皮癣剂和便秘剂。所审查的药物有贝曲沙班、甲磺酸沙非胺、甲磺酸缬苯那嗪、guselkumab和plecanatide。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CONSULTANT PHARMACIST
CONSULTANT PHARMACIST PHARMACOLOGY & PHARMACY-
自引率
0.00%
发文量
0
期刊介绍: Vision ... The Society"s long-term desire, aspiration, and core purpose. The vision of the American Society of Consultant Pharmacists is optimal medication management and improved health outcomes for all older persons. Mission ... The Society"s strategic position, focus, and reason for being. The American Society of Consultant Pharmacists empowers pharmacists to enhance quality of care for all older persons through the appropriate use of medication and the promotion of healthy aging.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信